Notwithstanding positive clinical evidence, copyright's Vyndamax, a treatment for hereditary transthyretin-mediated amyloidosis (hATTR), is facing considerable difficulty from managed care entities. The insurers are often creating obstacles to access, such as steep price criteria and approval processes that restrict consumer access. Market indicate